No More Transfusions!!! Dr. John Scarlett, President and CEO of Geron Corporation
Update: 2025-07-09
Description
Dr. John Scarlett, President and CEO of Geron Corporation talks about their drug Imetelstat for myelodysplastic syndrome (MDS). MDS patients often require frequent blood transfusions, impacting their quality of life. Imetelstat, a telomerase inhibitor, aims to reduce transfusion dependence by targeting cancer cells in the bone marrow. Phase three trials showed promising results, with 40% of patients experiencing at least an 8-week transfusion-free interval.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
